AUS
NZ
UK
CA
USA
IND
Headlines
- Stifel Nicolaus raises Envista's target price to $21.00.
- Multiple firms adjust their ratings on Envista.
- Revised outlook suggests positive momentum for the company.
Envista (NYSE:NVST) has received a revised price target from Stifel Nicolaus, moving it from $18.00 to $21.00. The updated target reflects a positive outlook for the dental products company, highlighting potential growth. Stifel Nicolaus remains optimistic about Envista's future performance.
Other financial institutions have weighed in with their evaluations. Wells Fargo initiated coverage of Envista, providing an "equal weight" rating, with a target price of $20.00. Meanwhile, JPMorgan Chase & Co. adjusted their stance, moving the company from an "overweight" rating to a "neutral" rating, reflecting adjustments in their target price from $23.00 to $16.00. Bank of America also revised its outlook, setting a price target of $19.00.
Piper Sandler made further adjustments, lowering their target from $18.00 to $16.00 while maintaining a neutral view. In contrast, Evercore ISI increased its price target, moving from $18.00 to $23.00, showing optimism for the company’s future prospects.
These adjustments reflect the varied opinions of analysts, with some maintaining a cautious approach and others signaling confidence in Envista's growth. Despite differing outlooks, the recent adjustments reflect ongoing interest in Envista's business model and potential.
Overall, while some firms have taken a more neutral stance, others, such as Stifel Nicolaus and Evercore ISI, have adjusted their outlook positively, suggesting the company's developments are being closely watched in the dental industry.
